Lamistar 150 mg/30 mg Tablet
By Lamistar
Rx
30 Tablet in a Strip

Composition
Lamivudine(150mg) + Stavudine(30mg)

Manufacturer - Hetero Drugs Ltd
7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad – 500 018. Telangana, INDIA

Expires on or after
September, 2025

liver
When it comes to using Lamistar 150 mg/30 mg Tablet, it is deemed generally safe for individuals with liver disease based on the limited data we have. There is no definitive need for adjusting the dosage of Lamistar 150 mg/30 mg Tablet in patients with liver issues. However, it is crucial to consult your doctor before starting this medication. If you experience any signs or symptoms of jaundice while on Lamistar 150 mg/30 mg Tablet, it is important to notify your doctor promptly, as discontinuation of the medicine may be necessary.

kidney
Lamistar 150 mg/30 mg Tablet requires caution in patients with kidney disease. Dosage adjustment might be necessary. It is advised to consult a doctor before use.

alcohol
When taking Lamistar 150 mg/30 mg Tablet, be cautious when drinking alcohol. It is recommended to consult your doctor regarding alcohol consumption.

driving
When taking Lamistar 150 mg/30 mg Tablet, be cautious when driving as it can reduce alertness, impact vision, and cause drowsiness and dizziness. Avoid driving if experiencing these symptoms.

pregnancy
Lamistar 150 mg/30 mg Tablet may be unsafe during pregnancy. Animal studies show harm to the baby. Consult your doctor for guidance on benefits versus risks.

breastfeeding
Lamistar 150 mg/30 mg Tablet is likely safe to use while breastfeeding. Human data indicates no significant risk to the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | - |
Action Class | - |
₹316.7
Inclusive of all taxes
Content verified by

Dr. Mansi Chaudhari
MBBS - General Medicine
Last update on 11-Feb-2025